{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:38:23Z","timestamp":1788021503568,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,18]]},"DOI":"10.7759\/cureus.101804","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:33:22Z","timestamp":1768786402000},"source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive Genomic Profiling Across Diverse Solid Tumors: A Real-World Experience From India With FoundationOne\u00aeCDx Testing"],"prefix":"10.7759","author":[{"given":"Pramod K","family":"Julka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm2010001","article-title":"Personalized Medicine and Cancer","volume":"4","author":"Verma M","year":"2012","unstructured":"Verma M. Personalized Medicine and Cancer. J Pers Med. 2012, 4:1-14. 10.3390\/jpm2010001","journal-title":"J Pers Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing genome-driven oncology","volume":"5","author":"Hyman DM","year":"2017","unstructured":"Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017, 5:584-99. 10.1016\/j.cell.2016.12.015","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.687730","article-title":"The impact of foundation medicine testing on cancer patients: a single academic centre experience","volume":"11","author":"Karol D","year":"2021","unstructured":"Karol D, McKinnon M, Mukhtar L, Awan A, Lo B, Wheatley-Price P. The impact of foundation medicine testing on cancer patients: a single academic centre experience. Front Oncol. 2021, 11:687730. 10.3389\/fonc.2021.687730","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo J","year":"2022","unstructured":"Mateo J, Steuten L, Aftimos P, et al.. Delivering precision oncology to patients with cancer. Nat Med. 2022, 28:658-65. 10.1038\/s41591-022-01717-2","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13091619","article-title":"Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: the experience of an academic hospital","volume":"13","author":"Teuwen LA","year":"2023","unstructured":"Teuwen LA, Roets E, D'Hoore P, Pauwels P, Prenen H. Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: the experience of an academic hospital. Diagnostics (Basel). 2023, 13:23-5. 10.3390\/diagnostics13091619","journal-title":"Diagnostics (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100487","article-title":"When should we order a next generation sequencing test in a patient with cancer?","volume":"25","author":"Colomer R","year":"2020","unstructured":"Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-Fandino M. When should we order a next generation sequencing test in a patient with cancer?. EClinicalMedicine. 2020, 25:100487. 10.1016\/j.eclinm.2020.100487","journal-title":"EClinicalMedicine"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/biology13050286","article-title":"Next-generation sequencing technology: current trends and advancements","volume":"13","author":"Satam H","year":"2023","unstructured":"Satam H, Joshi K, Mangrolia U, et al.. Next-generation sequencing technology: current trends and advancements. Biology (Basel). 2023, 13:286. 10.3390\/biology13050286","journal-title":"Biology (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13837","article-title":"Next generation sequencing-based gene panel tests for the management of solid tumors","volume":"110","author":"Nagahashi M","year":"2019","unstructured":"Nagahashi M, Shimada Y, Ichikawa H, Kameyama H, Takabe K, Okuda S, Wakai T. Next generation sequencing-based gene panel tests for the management of solid tumors. Cancer Sci. 2019, 110:6-15. 10.1111\/cas.13837","journal-title":"Cancer Sci"},{"key":"ref9","unstructured":"FDA. FDA Grants Marketing Approval to FoundationOne CDx In Vitro Diagnostic 2017. (2017). Accessed. January 17, 2026: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-marketing-approval-foundationone-cdx-in-vit...."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000385","article-title":"Clinical applications of next-generation sequencing in precision oncology","volume":"25","author":"Karlovich CA","year":"2019","unstructured":"Karlovich CA, Williams PM. Clinical applications of next-generation sequencing in precision oncology. Cancer J. 2019, 25:264-71. 10.1097\/PPO.0000000000000385","journal-title":"Cancer J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0049","article-title":"Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers","volume":"4","author":"Hirshfield KM","year":"2016","unstructured":"Hirshfield KM, Tolkunov D, Zhong H, et al.. Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers. Oncologist. 2016, 4:1315-25. 10.1634\/theoncologist.2016-0049","journal-title":"Oncologist"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.11571","article-title":"Clinical utility of molecular testing to select therapy in relapsed\/refractory non-Hodgkin lymphoma: Mayo Clinic Center for Individualized Medicine experience","volume":"8","author":"Bennani NN","year":"2017","unstructured":"Bennani NN, Ansell SM, Witzig TE, et al.. Clinical utility of molecular testing to select therapy in relapsed\/refractory non-Hodgkin lymphoma: Mayo Clinic Center for Individualized Medicine experience. J Clin Oncol. 2017, 8:11571-1. 10.1200\/JCO.2017.35.15_suppl.11571","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13639","article-title":"Clinical application of the FoundationOne CDx assay to therapeutic decision-making for patients with advanced solid tumors","volume":"26","author":"Takeda M","year":"2021","unstructured":"Takeda M, Takahama T, Sakai K, et al.. Clinical application of the FoundationOne CDx assay to therapeutic decision-making for patients with advanced solid tumors. Oncologist. 2021, 26:588-96. 10.1002\/onco.13639","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3007","article-title":"Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: interim analysis (IA) results","volume":"40","author":"Loriot Y","year":"2022","unstructured":"Loriot Y. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: interim analysis (IA) results. J Clin Oncol. 2022, 40:3007. 10.1200\/JCO.2022.40.16_suppl.3007","journal-title":"J Clin Oncol"},{"key":"ref15","unstructured":"FoundationOne CDx. technical specification. (2023). Accessed: January 17, 2026: https:\/\/info.foundationmedicine.com\/hubfs\/FMI%20Labels\/FoundationOne_CDx_Label_Technical_Info.pdf."},{"key":"ref16","unstructured":"FoundationOne CDx. (2022). Accessed. January 17, 2026: https:\/\/www.foundationmedicine.com."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01502-x","article-title":"Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study","volume":"125","author":"Gambardella V","year":"2021","unstructured":"Gambardella V, Lombardi P, Carbonell-Asins JA, et al.. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Br J Cancer. 2021, 125:1261-9. 10.1038\/s41416-021-01502-x","journal-title":"Br J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz245","article-title":"The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design","volume":"1","author":"Flaherty KT","year":"2020","unstructured":"Flaherty KT, Gray R, Chen A, et al.. The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design. J Natl Cancer Inst. 2020, 1:1021-9. 10.1093\/jnci\/djz245","journal-title":"J Natl Cancer Inst"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-014-0031-6","article-title":"Driver mutations of cancer epigenomes","volume":"4","author":"Roy DM","year":"2014","unstructured":"Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell. 2014, 4:265-96. 10.1007\/s13238-014-0031-6","journal-title":"Protein Cell"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84909-9","article-title":"Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital","volume":"16","author":"Kim JW","year":"2025","unstructured":"Kim JW, Na HY, Lee S, et al.. Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital. Sci Rep. 2025, 16:2171. 10.1038\/s41598-024-84909-9","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-083115-022413","article-title":"Advancements in next-generation sequencing","volume":"31","author":"Levy SE","year":"2016","unstructured":"Levy SE, Myers RM. Advancements in next-generation sequencing. Annu Rev Genomics Hum Genet. 2016, 31:95-115. 10.1146\/annurev-genom-083115-022413","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.c211","article-title":"Role of tumor molecular profiling with FoundationOne\u00aeCDx in advanced solid tumors: a single-centre experience from Romania","volume":"18","author":"Popa AM","year":"2023","unstructured":"Popa AM, Stejeroiu MA, Iaciu C, et al.. Role of tumor molecular profiling with FoundationOne\u00aeCDx in advanced solid tumors: a single-centre experience from Romania. Cureus. 2023, 18:50709-10. 10.7759\/cureus.c211","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.11.010","article-title":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","volume":"31","author":"Barroso-Sousa R","year":"2020","unstructured":"Barroso-Sousa R, Jain E, Cohen O, et al.. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 2020, 31:387-94. 10.1016\/j.annonc.2019.11.010","journal-title":"Ann Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104423","article-title":"Comprehensive genomic profiling can predict response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"80","author":"Drobniene M","year":"2025","unstructured":"Drobniene M, Breimelyte D, Sadzeviciene I, et al.. Comprehensive genomic profiling can predict response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast. 2025, 80:104423-10. 10.1016\/j.breast.2025.104423","journal-title":"Breast"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_432_20","article-title":"NGS-based profiling of key cancer genes in Indian triple-negative breast cancer patients reinforces molecular heterogeneity of the disease","volume":"58","author":"Sahasrabuddhe NA","year":"2021","unstructured":"Sahasrabuddhe NA, Korlimarla A, Kulkarni M, et al.. NGS-based profiling of key cancer genes in Indian triple-negative breast cancer patients reinforces molecular heterogeneity of the disease. Indian J Cancer. 2021, 58:598-602. 10.4103\/ijc.IJC_432_20","journal-title":"Indian J Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67393-9","article-title":"Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients","volume":"26","author":"Hempel D","year":"2020","unstructured":"Hempel D, Ebner F, Garg A, et al.. Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients. Sci Rep. 2020, 26:10459. 10.1038\/s41598-020-67393-9","journal-title":"Sci Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00303-6","article-title":"Impact of TP53 mutations in triple negative breast cancer","volume":"6","author":"Mitri ZI","year":"2022","unstructured":"Mitri ZI, Abuhadra N, Goodyear SM, Hobbs EA, Kaempf A, Thompson AM, Moulder SL. Impact of TP53 mutations in triple negative breast cancer. NPJ Precis Oncol. 2022, 6:64. 10.1038\/s41698-022-00303-6","journal-title":"NPJ Precis Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90243-6","article-title":"Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53","volume":"70","author":"Livingstone LR","year":"1992","unstructured":"Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 1992, 70:923-35. 10.1016\/0092-8674(92)90243-6","journal-title":"Cell"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai799344","article-title":"Genomic profiling of ER+breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance","volume":"7620","author":"Giltnane JM","year":"2019","unstructured":"Giltnane JM, Hutchinson KE, Stricker TP, et al.. Genomic profiling of ER+breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2019, 7620:7993. 10.1126\/scitranslmed.aai799344","journal-title":"Sci Transl Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S360177","article-title":"Clinical impact of 11q13.3 amplification on immune cell infiltration and prognosis in breast cancer","volume":"15","author":"Zhou R","year":"2022","unstructured":"Zhou R, Zhu X, Peng Y, et al.. Clinical impact of 11q13.3 amplification on immune cell infiltration and prognosis in breast cancer. Int J Gen Med. 2022, 15:4037-52. 10.2147\/IJGM.S360177","journal-title":"Int J Gen Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0378","article-title":"Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies","volume":"20","author":"Ali SM","year":"2015","unstructured":"Ali SM, Sanford EM, Klempner SJ, et al.. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist. 2015, 20:499-507. 10.1634\/theoncologist.2014-0378","journal-title":"Oncologist"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.398","article-title":"486P Genomic profile differences between primary and recurrent tumors in curatively resected gastric cancer: The Liquid-GEAR study","volume":"193","author":"Takeda H","year":"2024","unstructured":"Takeda H, Kawabata R, Ishiguro A, et al.. 486P Genomic profile differences between primary and recurrent tumors in curatively resected gastric cancer: The Liquid-GEAR study. Ann Oncol. 2024, 193:8-10. 10.1016\/j.annonc.2024.05.398","journal-title":"Ann Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s44411-025-00460-7","article-title":"Advancing therapeutic strategies for pancreatic cancer: a review of surgical, systemic and diagnostic innovations","volume":"14","author":"Hidig SM","year":"2025","unstructured":"Hidig SM, Mujahid MUF, Kitaghenda FK, Hu z. Advancing therapeutic strategies for pancreatic cancer: a review of surgical, systemic and diagnostic innovations. Bratisl Med J. 2025, 14:32-4. 10.1007\/s44411-025-00460-7","journal-title":"Bratisl Med J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf390","article-title":"Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne\u00aeCDx compared with amplicon-based OncomineDX","volume":"30","author":"Chen KT","year":"2025","unstructured":"Chen KT, Sethunath V, Ebot E, et al.. Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne\u00aeCDx compared with amplicon-based OncomineDX. Oncologist. 2025, 30:16-8. 10.1093\/oncolo\/oyaf390","journal-title":"Oncologist"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051352","article-title":"The clinical utility and impact of next generation sequencing in gynecologic cancers","volume":"7","author":"Maruthi VK","year":"2022","unstructured":"Maruthi VK, Khazaeli M, Jeyachandran D, et al.. The clinical utility and impact of next generation sequencing in gynecologic cancers. Cancers (Basel). 2022, 7:1352. 10.3390\/cancers14051352","journal-title":"Cancers (Basel)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa256","article-title":"The utility of next-generation sequencing in advanced breast and gynecologic cancers","volume":"156","author":"Jones TE","year":"2021","unstructured":"Jones TE, Zou J, Tseng GC, Roy S, Bhargava R. The utility of next-generation sequencing in advanced breast and gynecologic cancers. Am J Clin Pathol. 2021, 156:455-60. 10.1093\/ajcp\/aqaa256","journal-title":"Am J Clin Pathol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.06.015","article-title":"Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer","volume":"37","author":"Zhu J","year":"2019","unstructured":"Zhu J, Tucker M, Marin D, et al.. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urol Oncol. 2019, 37:813.e1-9. 10.1016\/j.urolonc.2019.06.015","journal-title":"Urol Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030719","article-title":"Clinical utility of comprehensive genomic profiling in patients with unresectable hepatocellular carcinoma","volume":"15","author":"Ishido S","year":"2023","unstructured":"Ishido S, Tsuchiya K, Kano Y, et al.. Clinical utility of comprehensive genomic profiling in patients with unresectable hepatocellular carcinoma. Cancers (Basel). 2023, 15:16-8. 10.3390\/cancers15030719","journal-title":"Cancers (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/455781-comprehensive-genomic-profiling-across-diverse-solid-tumors-a-real-world-experience-from-india-with-foundationonecdx-testing","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:33:23Z","timestamp":1768786403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/455781-comprehensive-genomic-profiling-across-diverse-solid-tumors-a-real-world-experience-from-india-with-foundationonecdx-testing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,18]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.101804","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,18]]}}}